Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLR3: Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia
NCT00967057Phase 3Completed
- Sponsor
- Children's Cancer and Leukaemia Group
- Start
- Oct 2002
- Primary completion
- Jan 2010
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of idarubicin, mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in acute lymphoblastic leukemia (ALL), sponsored by Children's Cancer and Leukaemia Group. Started Oct 2002; status: completed.
02
Drugs
idarubicinmitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00967057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00967057.